Barrera-Salas M, Hernández-Salcedo DR, Valencia-López R

Language: Spanish
References: 17
Page: 308-312
PDF size: 194.73 Kb.

ABSTRACT

Hyperkalemia induced by trimethoprim-sulfamethoxazole therapy, described in 1983, is a frequent, yet less thought-off complication that can be dangerous and can cause death. There are conditions that increase the risk of presenting it, including, for example, diabetes mellitus and the use of renin-angiotensin system inhibition. This paper describes the case of a female patient who, on the third day of administration of trimethoprim-sulfamethoxazole for the management of a recurrent urinary tract infection, presented severe hyperkalemia, in the context of concomitant use of reninangiotensin system inhibition, that was cured with antikalemic measures and with the suspension of antibiotic treatment.

REFERENCES

1. Masters P, et al. Trimethoprim-sulfamethoxazole Revised. Arch Intern Med 2003;163, Feb 23: 2003.

2. Parazella, M. Trimethoprim-induced hyperkalaemia, clinical data, mechanism, prevention and management. Drug Safety 2000 Mar;22(3):227-236.

3. Díaz J, Fernández L. Reporte de caso: Hiperpotasemia inducida por trimetoprim-sulfametoxasol en un paciente con insuficiencia suprarrenal primaria. Asociación Colombiana de Infectología. Revista Infectio 2010;14(3):223- 226.

4. Ho J, Juurlink D. Considerations when prescribing trimethoprim- sulfamethoxazole. CMAJ November 8, 2011;183(16).

5. Perazella MA. Hyperkalemia and trimethoprim-sulfamethoxazole: a new problem emerges 25 years later. Conn Med1997 Aug;61(8):451-8.

6. Nickels C, Jones C, Ganti L. Case report trimethoprimsulfamethoxazole- induced hyperkalemia in a patient with normal renal function. Case Reports in Emergency Medicine Volume 2012, Article ID 815907, 3 pages.

7. McDonald T, Oram R, Vaidya B. Investigating hyperkalaemia in adults. BMJ 2015;351:h4762.

8. Palmer BF, Clegg DJ. Hyperkalemia. JAMA December 8, 2015;314(22).

9. Fordjour K, et al. Management of hyperkalemia in hospitalized patients. Am J Med Sci 2014;347(2).

10. Fralick M, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 2014;349:g6196.

11. Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN. Canadian drug safety and effectiveness research network. Trimethoprim- sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ 2015.

12. Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the reninangiotensin system: a population-based study. Arch Intern Med 2010;170:1045-9.

13. Kennard A. Medical mishap. Trimethoprim-induced critical hyperkalemia. Aust Prescr 2016;39:136-7.

14. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652-8.

15. Fraser T, et al. Acute kidney injury associated with trimethoprim/ sulfamethoxazole. J Antimicrob Chemother 2012;67:1271-1277.

16. Palmer B. A physiologic-based approach to the evaluation of a patient with hyperkalemia. Am J Kidney Dis 2010;56(2) August):387-393.

17. Concha G, Seguel A, Abuter S, Kelly M, Alarcón F. Pseudohyperkalemia in essential thrombocytosis: a poorly recognized entity. Rev ANACEM 2015;9(1):17-21.